BG108261A - Фармацевтични комбинации, основани на пиридоиндолонови производни и противоракови средства - Google Patents

Фармацевтични комбинации, основани на пиридоиндолонови производни и противоракови средства Download PDF

Info

Publication number
BG108261A
BG108261A BG108261A BG10826103A BG108261A BG 108261 A BG108261 A BG 108261A BG 108261 A BG108261 A BG 108261A BG 10826103 A BG10826103 A BG 10826103A BG 108261 A BG108261 A BG 108261A
Authority
BG
Bulgaria
Prior art keywords
methyl
group
formula
hydrogen
atom
Prior art date
Application number
BG108261A
Other languages
Bulgarian (bg)
English (en)
Inventor
Bernard Bourrie
Pierre Casellas
Jean-Marie Derocq
Original Assignee
Sanofi - Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi - Synthelabo filed Critical Sanofi - Synthelabo
Publication of BG108261A publication Critical patent/BG108261A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG108261A 2001-04-27 2003-10-13 Фармацевтични комбинации, основани на пиридоиндолонови производни и противоракови средства BG108261A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone

Publications (1)

Publication Number Publication Date
BG108261A true BG108261A (bg) 2004-12-30

Family

ID=8862882

Family Applications (2)

Application Number Title Priority Date Filing Date
BG108261A BG108261A (bg) 2001-04-27 2003-10-13 Фармацевтични комбинации, основани на пиридоиндолонови производни и противоракови средства
BG108260A BG108260A (bg) 2001-04-27 2003-10-13 Приложение на пиридоиндолонови производни за получаване на противоракови лекарства

Family Applications After (1)

Application Number Title Priority Date Filing Date
BG108260A BG108260A (bg) 2001-04-27 2003-10-13 Приложение на пиридоиндолонови производни за получаване на противоракови лекарства

Country Status (34)

Country Link
US (3) US6967203B2 (ru)
EP (2) EP1385513B1 (ru)
JP (2) JP2004531538A (ru)
KR (1) KR100847413B1 (ru)
CN (2) CN1240382C (ru)
AR (1) AR034313A1 (ru)
AT (2) ATE338548T1 (ru)
BG (2) BG108261A (ru)
BR (1) BR0209138A (ru)
CA (2) CA2443012C (ru)
CY (1) CY1105813T1 (ru)
CZ (2) CZ299465B6 (ru)
DE (2) DE60208365T2 (ru)
DK (2) DK1385513T3 (ru)
EA (1) EA005930B1 (ru)
EE (2) EE200300465A (ru)
ES (2) ES2254683T3 (ru)
FR (1) FR2823975B1 (ru)
HK (2) HK1059895A1 (ru)
HU (2) HUP0400745A2 (ru)
IL (4) IL158266A0 (ru)
IS (1) IS2441B (ru)
MX (1) MXPA03009639A (ru)
NO (2) NO20034785L (ru)
NZ (1) NZ528671A (ru)
PL (2) PL366916A1 (ru)
PT (2) PT1385512E (ru)
RS (2) RS50791B (ru)
RU (1) RU2292888C9 (ru)
SK (2) SK13242003A3 (ru)
TW (1) TWI252104B (ru)
UA (1) UA74876C2 (ru)
WO (2) WO2002087575A1 (ru)
ZA (1) ZA200307785B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2846329B1 (fr) * 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) * 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
ATE386131T1 (de) * 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
FR2765582B1 (fr) 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
FR2765581B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
AU3375999A (en) * 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino(2,3-b)indole and 5,6,7,8-tetrahydro-9h-pyrimidino(4,5-b)indole derivatives: crf1 specific ligands
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CA2443012C (fr) 2009-07-28
NO20034787L (no) 2003-12-23
PL366916A1 (en) 2005-02-07
EE200300466A (et) 2003-12-15
RS50791B (sr) 2010-08-31
KR20040015138A (ko) 2004-02-18
NO20034785L (no) 2003-12-23
RU2292888C9 (ru) 2007-06-20
PT1385512E (pt) 2006-05-31
DE60214533T2 (de) 2007-06-21
NO20034787D0 (no) 2003-10-24
KR100847413B1 (ko) 2008-07-18
YU83903A (sh) 2006-08-17
US7524857B2 (en) 2009-04-28
AR034313A1 (es) 2004-02-18
DE60208365T2 (de) 2006-09-07
ZA200307785B (en) 2004-10-06
SK13242003A3 (sk) 2004-03-02
YU83403A (sh) 2006-08-17
IS6984A (is) 2003-10-09
IL158312A0 (en) 2004-05-12
DE60208365D1 (de) 2006-02-02
IL158266A0 (en) 2004-05-12
PL366910A1 (en) 2005-02-07
CZ295224B6 (cs) 2005-06-15
CN1240382C (zh) 2006-02-08
US20050272760A1 (en) 2005-12-08
SK13252003A3 (sk) 2004-03-02
CY1105813T1 (el) 2011-02-02
BR0209138A (pt) 2004-06-08
MXPA03009639A (es) 2004-06-30
PT1385513E (pt) 2007-01-31
FR2823975B1 (fr) 2003-05-30
JP2004531538A (ja) 2004-10-14
RS50790B (sr) 2010-08-31
CZ20032909A3 (en) 2004-06-16
NZ528671A (en) 2004-06-25
US6967203B2 (en) 2005-11-22
EP1385513A1 (fr) 2004-02-04
CA2443012A1 (en) 2002-11-07
FR2823975A1 (fr) 2002-10-31
CN1505511A (zh) 2004-06-16
EA200301062A1 (ru) 2004-04-29
DK1385512T3 (da) 2006-05-22
UA74876C2 (en) 2006-02-15
HK1059895A1 (en) 2004-07-23
EP1385512B1 (fr) 2005-12-28
IL158312A (en) 2009-09-01
HK1060066A1 (en) 2004-07-30
IL158266A (en) 2009-09-01
WO2002087574A3 (fr) 2003-02-13
CA2444334A1 (fr) 2002-11-07
ES2271264T3 (es) 2007-04-16
ES2254683T3 (es) 2006-06-16
EA005930B1 (ru) 2005-08-25
RU2003130376A (ru) 2005-04-10
CZ20032910A3 (en) 2004-07-14
EP1385512A2 (fr) 2004-02-04
DK1385513T3 (da) 2007-01-15
JP2004528343A (ja) 2004-09-16
CN1505510A (zh) 2004-06-16
ATE314070T1 (de) 2006-01-15
BG108260A (bg) 2004-12-30
HUP0400744A2 (hu) 2004-06-28
EE200300465A (et) 2003-12-15
TWI252104B (en) 2006-04-01
WO2002087574A2 (fr) 2002-11-07
HUP0400745A2 (hu) 2004-08-30
DE60214533D1 (de) 2006-10-19
RU2292888C2 (ru) 2007-02-10
NO20034785D0 (no) 2003-10-24
US20040122027A1 (en) 2004-06-24
WO2002087575A1 (fr) 2002-11-07
ATE338548T1 (de) 2006-09-15
US20040122036A1 (en) 2004-06-24
EP1385513B1 (fr) 2006-09-06
IS2441B (is) 2008-11-15
CZ299465B6 (cs) 2008-08-06
US7160895B2 (en) 2007-01-09

Similar Documents

Publication Publication Date Title
DK2979700T3 (en) ANTITUMUM AGENT CONTAINING A LOW IRINOTECAN HYDROCHLORIDE HYDRATE
US7160895B2 (en) Use of pyridoindolone derivatives for the preparation of medicinal products
US20090042924A1 (en) Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics
CN109152750B (zh) 用于增殖性疾病的组合疗法
RU2657604C2 (ru) Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана
AU2013235275A1 (en) Methods of treating cancer using aurora kinase inhibitors
JP2011514356A5 (ru)
NZ740252B2 (en) Antitumor agent including low-dose irinotecan hydrochloride hydrate
NZ740252A (en) Antitumor agent including low-dose irinotecan hydrochloride hydrate
KR20060007368A (ko) Ｎ-(3-클로로-1ｈ-인돌-7-일)-4-설파모일벤젠설폰아미드를포함하는 약제 조성물 및 세포 증식 억제제
JP2015199677A (ja) ノギテカン塩酸塩を含有する抗腫瘍剤及び抗腫瘍効果増強剤